Total Valuation
Virax Biolabs Group Ltd. Class A has a market cap or net worth of $2.09M. The enterprise value is -$2.07M.
Market Cap$2.09M
Enterprise Value-$2.07M
Share Statistics
Virax Biolabs Group Ltd. Class A has 796,988 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding796,988
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Virax Biolabs Group Ltd. Class A’s return on equity (ROE) is -0.66 and return on invested capital (ROIC) is -82.58%.
Return on Equity (ROE)-0.66
Return on Assets (ROA)-0.60
Return on Invested Capital (ROIC)-82.58%
Return on Capital Employed (ROCE)-0.84
Revenue Per Employee477.81
Profits Per Employee-193.22K
Employee Count26
Asset Turnover<0.01
Inventory Turnover0.10
Valuation Ratios
The current PE Ratio of Virax Biolabs Group Ltd. Class A is ―. Virax Biolabs Group Ltd. Class A’s PEG ratio is 0.00586.
PE Ratio―
PS Ratio175.96
PB Ratio0.29
Price to Fair Value0.29
Price to FCF-0.45
Price to Operating Cash Flow-0.37
PEG Ratio0.00586
Income Statement
In the last 12 months, Virax Biolabs Group Ltd. Class A had revenue of 12.42K and earned -5.02M in profits. Earnings per share was -12.64.
Revenue12.42K
Gross Profit7.69K
Operating Income-6.40M
Pretax Income-5.93M
Net Income-5.02M
EBITDA-5.43M
Earnings Per Share (EPS)-12.64
Cash Flow
In the last 12 months, operating cash flow was -4.79M and capital expenditures -255.83K, giving a free cash flow of -5.04M billion.
Operating Cash Flow-4.79M
Free Cash Flow-5.04M
Free Cash Flow per Share-6.32
Dividends & Yields
Virax Biolabs Group Ltd. Class A pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.74
52-Week Price Change-85.18%
50-Day Moving Average3.94
200-Day Moving Average6.72
Relative Strength Index (RSI)43.22
Average Volume (3m)315.79K
Important Dates
Virax Biolabs Group Ltd. Class A upcoming earnings date is Feb 2, 2023, TBA (Confirmed).
Last Earnings DateInvalid Date
Next Earnings DateFeb 2, 2023
Ex-Dividend Date―
Financial Position
Virax Biolabs Group Ltd. Class A as a current ratio of 9.97, with Debt / Equity ratio of 5.47%
Current Ratio9.97
Quick Ratio9.90
Debt to Market Cap0.01
Net Debt to EBITDA1.00
Interest Coverage Ratio-103.60
Taxes
In the past 12 months, Virax Biolabs Group Ltd. Class A has paid -900.24K in taxes.
Income Tax-900.24K
Effective Tax Rate-0.15
Enterprise Valuation
Virax Biolabs Group Ltd. Class A EV to EBITDA ratio is 0.63, with an EV/FCF ratio of 0.79.
EV to Sales-308.99
EV to EBITDA0.63
EV to Free Cash Flow0.79
EV to Operating Cash Flow0.83
Balance Sheet
Virax Biolabs Group Ltd. Class A has $6.52M in cash and marketable securities with $414.39K in debt, giving a net cash position of $6.10M billion.
Cash & Marketable Securities$6.52M
Total Debt$414.39K
Net Cash$6.10M
Net Cash Per Share$7.66
Tangible Book Value Per Share$18.46
Margins
Gross margin is 61.90%, with operating margin of -51515.17%, and net profit margin of -40439.10%.
Gross Margin61.90%
Operating Margin-51515.17%
Pretax Margin-47753.55%
Net Profit Margin-40439.10%
EBITDA Margin-48685.09%
EBIT Margin-51515.17%
Analyst Forecast
The average price target for Virax Biolabs Group Ltd. Class A is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast96.22%
EPS Growth Forecast58.99%